NeoZanHER, the phase 2 trial of zanidatamab in early-stage HER2-positive breast cancer, reported promising activity designed to move antibody therapy into the pre-surgery setting. The trial evaluates zanidatamab, a next-generation HER2-targeted antibody intended to attack the receptor via two binding modes. Published in Nature Communications in 2026, the study reflects continued momentum toward neoadjuvant strategies aimed at shrinking tumors and increasing pathological response rates. For developers, preoperative settings can also generate faster translational readouts that may inform later-stage registrational designs. The work underscores the competitive race in HER2 management—particularly in differentiating mechanisms of action and defining which response metrics best predict long-term outcomes.